IMR Press / FBS / Volume 3 / Issue 4 / DOI: 10.2741/235

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

P2 receptors and extracellular ATP: a novel homeostatic pathway in inflammation
Show Less
1 Maastricht University, School for Public Health and Primary Care (CAPHRI), P.O. Box 616, 6200 MD Maastricht, The Netherlands
2 University of Ferrara, Department of Experimental and Diagnostic Medicine, Section of General Pathology, Via Borsari 46, I-44100 Ferrara, Italy
3 Interdisciplinary Center for the Study in Inflammation, Via Borsari 46, I-44100 Ferrara, Italy

*Author to whom correspondence should be addressed.

Academic Editor: Xueji Zhang

Front. Biosci. (Schol Ed) 2011, 3(4), 1443–1456;
Published: 1 June 2011
(This article belongs to the Special Issue Biosensors and their applications)

Inflammation is an important homeostatic response, which is managed by a complex network of interrelated pathways that determine the level, intensity and localization of inflammation. We now know that purinergic signalling is one of the pathways influencing the initiation, progression and down-modulation of the inflammatory response. Here, we review recent evidence on the role in inflammation of the purinergic signalling system, which is comprised of extracellular ATP, P2 receptors and ecto-enzyme cascades. Recent animal studies with a newly developed bioluminescent ATP probe (pmeLUC), enabling measurement of pericellular ATP in situ, have provided proof that ATP is present in inflamed tissues in vivo at extracellular concentrations sufficient for P2 receptor activation. Increased extracellular ATP levels amplify inflammation in vivo by promoting leukocyte recruitment and NALP3-inflammasome activation via P2X7. Lowering extracellular ATP levels in inflamed tissues, for instance by stimulating its breakdown, inhibits the inflammatory response in vivo. In view of its important role in inflammation, the purinergic signalling system is bound to yield novel therapeutic opportunities for the treatment of inflammatory diseases.

Back to top